Why the study?
Do baseline serum cardiac biomarkers predict functional outcomes and risk in patients with acute ischemic stroke undergoing reperfusion therapy?
Population
433 patients with acute ischemic stroke treated with intravenous thrombolysis, mechanical thrombectomy, or…
Design
Cohort
Follow-up
3 months
Key result
Elevated baseline hs-cTnT (>10.5 pg/mL) and LDH (>200 U/L) independently predicted poor 3-month functional outcomes in acute ischemic stroke patients (OR 1.685 and 1.845, respectively; p<0.05).
Authors
Loading...
May aid post-reperfusion risk stratification in AIS; hypothesis-generating and requires prospective validation before clinical adoption.
Cohort (n=433)
Do baseline serum cardiac biomarkers predict functional outcomes and risk in patients with acute ischemic stroke undergoing reperfusion therapy?
Odds Ratio: 1.685
p-value: p=<0.05
Elevated baseline hs-cTnT and LDH levels independently predict poor 3-month functional outcomes in patients with acute ischemic stroke undergoing reperfusion therapy.
Aslan et al. (2026) conducted a cohort in Acute ischemic stroke (n=433). Elevated baseline serum cardiac biomarkers (hs-cTnT >10.5 pg/mL and LDH >200 U/L) vs. Lower biomarker levels was evaluated on Poor 3-month prognosis (OR 1.685, p=<0.05). Elevated baseline hs-cTnT (>10.5 pg/mL) and LDH (>200 U/L) independently predicted poor 3-month functional outcomes in acute ischemic stroke patients (OR 1.685 and 1.845, respectively; p<0.05).